Iron chelation therapy for transfusional iron overload: A swift evolution

Hemoglobin

Volumn 35, Issue 5-6, 2011, Pages 565-573

  Musallam, Khaled M ^a   Taher, Ali T ^a  

^a AMERICAN UNIVERSITY OF BEIRUT   (Lebanon)

Author keywords

Chelation; Deferasirox (DFRA); Deferiprone (L1); Deferoxamine (DFO); Iron overload; Transfusion

Indexed keywords

ANTIBIOTIC AGENT; DEFERASIROX; DEFERIPRONE; FERRITIN; GRANULOCYTE COLONY STIMULATING FACTOR; IRON CHELATING AGENT;

AGRANULOCYTOSIS; ANTIBIOTIC THERAPY; ARTHRALGIA; ARTHROPATHY; BETA THALASSEMIA; BINDING AFFINITY; CHELATION THERAPY; CHRONIC TRANSFUSIONAL IRON OVERLOAD; COST EFFECTIVENESS ANALYSIS; CREATININE BLOOD LEVEL; DRUG CONTRAINDICATION; DRUG DOSE COMPARISON; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG ERUPTION; DRUG INDICATION; DRUG SAFETY; DRUG SPECIFICITY; DRUG TOLERABILITY; FERRITIN BLOOD LEVEL; GASTROINTESTINAL HEMORRHAGE; GASTROINTESTINAL SYMPTOM; GROWTH DISORDER; HIGH RISK PATIENT; HUMAN; IRON CHELATION; IRON OVERLOAD; LIVER FAILURE; MYELODYSPLASTIC SYNDROME; NUCLEAR MAGNETIC RESONANCE IMAGING; PATIENT COMPLIANCE; PATIENT SATISFACTION; POPULATION RESEARCH; PRESCRIPTION; REVIEW; SICKLE CELL ANEMIA; SIDE EFFECT; SIDEROSIS; SWELLING; ZINC DEFICIENCY;

BENZOIC ACIDS; BLOOD TRANSFUSION; CHELATION THERAPY; HUMANS; IRON CHELATING AGENTS; IRON OVERLOAD; PYRIDONES; TREATMENT OUTCOME; TRIAZOLES;

EID: 81055144357     PISSN: 03630269     EISSN: 1532432X     Source Type: Journal    
DOI: 10.3109/03630269.2011.608228     Document Type: Review

References (41)

1. Taher AT, Musallam KM, Inati A. Iron overload: consequences, assessment, and monitoring. Hemoglobin. 2009;33(Suppl. 1):S46-S57.
2. Brittenham GM. Iron-chelating therapy for transfusional iron overload. N Engl J Med. 2011;364(2):146-156.
3. Olivieri NF, Nathan DG, MacMillan JH, et al. Survival inmedically treated patients with homozygous β-thalassemia. N Engl J Med. 1994;331(9):574-578. (Pubitemid 24265699)
4. Borgna-Pignatti C, Rugolotto S, De Stefano P, et al. Survival and complications in patients with thalassemia major treated with transfusion and deferoxamine. Haematologica. 2004;89(10): 1187-1193. (Pubitemid 39390442)
5. * cardiovascular magnetic resonance. J Cardiovasc Magn Reson. 2008;10:42.
6. Delea TE, Edelsberg J, Sofrygin O, et al. Consequences and costs of noncompliance with iron chelation therapy in patients with transfusion-dependent thalassemia: a literature review. Transfusion. 2007;47(10):1919-1929. (Pubitemid 47438560)
7. Musallam K, Cappellini MD, Taher A. Challenges associated with prolonged survival of patients with thalassemia: transitioning from childhood to adulthood. Pediatrics. 2008;121(5):e1426-e1429.
8. Gabutti V, Piga A. Results of long-term iron-chelating therapy. Acta Haematol. 1996;95(1):26-36. (Pubitemid 26071428)
9. Kontoghiorghes GJ, Aldouri MA, Sheppard L, Hoffbrand AV. 1,2-Dimethyl-3-hydroxypyrid-4-one, an orally active chelator for treatment of iron overload. Lancet. 1987;1(8545):1294-1295. (Pubitemid 17072195)
10. Piga A, Roggero S, Salussolia I, Massano D, Serra M, Longo F. Deferiprone. Ann NY Acad Sci. 2010;1202:75-78.
11. Pennell DJ, Berdoukas V, Karagiorga M, et al. Randomized controlled trial of deferiprone or deferoxamine in β-thalassemia major patients with asymptomatic myocardial siderosis. Blood. 2006;107(9):3738-3744.
12. Anderson LJ, Wonke B, Prescott E, Holden S, Walker JM, Pennell DJ. Comparison of effects of oral deferiprone and subcutaneous desferrioxamine on myocardial iron concentrations and ventricular function in β-thalassaemia. Lancet. 2002;360(9332):516-520. (Pubitemid 35232104)
13. Borgna-Pignatti C, Cappellini MD, De Stefano P, et al. Cardiac morbidity and mortality in deferoxamine- or deferiprone-treated patients with thalassemia major. Blood. 2006;107(9): 3733-3737.
14. Piga A, Gaglioti C, Fogliacco E, Tricta F. Comparative effects of deferiprone and deferoxamine on survival and cardiac disease in patients with thalassemia major: a retrospective analysis. Haematologica. 2003;88(5):489-496. (Pubitemid 36648438)
15. Maggio A, Vitrano A, Capra M, et al. Improving survival with deferiprone treatment in patients with thalassemia major: a prospective multicenter randomised clinical trial under the auspices of the Italian Society for Thalassemia and Hemoglobinopathies. Blood Cells Mol Dis. 2009;42(3):247-251.
16. Wonke B, Wright C, Hoffbrand AV. Combined therapy with deferiprone and desferrioxamine. Br J Haematol. 1998;103(2):361-364. (Pubitemid 28522439)
17. Galanello R, Agus A, Campus S, Danjou F, Giardina PJ, Grady RW. Combined iron chelation therapy. Ann NY Acad Sci. 2010;1202:79-86.
18. Tanner MA, Galanello R, Dessi C, et al. A randomized, placebo-controlled, double-blind trial of the effect of combined therapy with deferoxamine and deferiprone on myocardial iron in thalassemia major using cardiovascular magnetic resonance. Circulation. 2007;115(14):1876-1884. (Pubitemid 46598901)
19. LaiME, Grady RW, Vacquer S, et al. Increased survival and reversion of iron-induced cardiac disease in patients with thalassemia major receiving intensive combined chelation therapy as compared to desferoxamine alone. Blood Cells Mol Dis. 2010;45(2):136-139.
20. Telfer PT,Warburton F, Christou S, et al. Improved survival in thalassemia major patients on switching from desferrioxamine to combined chelation therapy with desferrioxamine and deferiprone. Haematologica. 2009;94(12):1777-1778.
21. Cappellini MD, Musallam KM, Taher AT. Overview of iron chelation therapy with desferrioxamine and deferiprone. Hemoglobin. 2009;33(Suppl. 1):S58-S69.
22. Cappellini MD, Taher A. Long-term experience with deferasirox (ICL670), a once-daily oral iron chelator, in the treatment of transfusional iron overload. Expert Opin Pharmacother. 2008;9(13):2391-2402.
23. Cappellini MD, Cohen A, Piga A, et al. A phase 3 study of deferasirox (ICL670), a once-daily oral iron chelator, in patients with β-thalassemia. Blood. 2006;107(9):3455-3462.
24. Cappellini MD, Bejaoui M, Agaoglu L, et al. Iron chelation with deferasirox in adult and pediatric patients with thalassemia major: efficacy and safety during 5 years' follow-up. Blood. 2009;DO1 10.1182/blood-2010-11-316646.
25. Cappellini MD, Taher A. Deferasirox (Exjade) for the treatment of iron overload. Acta Haematol. 2009;122(2-3):165-173.
26. Vichinsky E, Onyekwere O, Porter J, et al. A randomised comparison of deferasirox versus deferoxamine for the treatment of transfusional iron overload in sickle cell disease. Br J Haematol. 2007;136(3):501-508. (Pubitemid 46046309)
27. Porter J, Galanello R, Saglio G, et al. Relative response of patients with myelodysplastic syndromes and other transfusion-dependent anaemias to deferasirox (ICL670): a 1-yr prospective study. Eur J Haematol. 2008;80(2):168-176.
28. Taher A, El-Beshlawy A, Elalfy MS, et al. Efficacy and safety of deferasirox, an oral iron chelator, in heavily iron-overloaded patients with β-thalassaemia: the ESCALATOR study. Eur J Haematol. 2009;82(6):458-465.
29. Taher A, Cappellini MD, Vichinsky E, et al. Efficacy and safety of deferasirox doses of >30 mg/kg per d in patients with transfusion-dependent anaemia and iron overload. Br J Haematol. 2009;147(5):752-759.
30. Porter JB, Piga A, Cohen A, et al. Safety of deferasirox (Exjade®) in patients with transfusiondependent anemias and iron overload who achieve serum ferritin levels <1000 ng/ml during longterm treatment abstract 5423 Blood 2008 112 11 5423
31. Cappellini MD, Bejaoui M, Agaoglu L, et al. Prospective evaluation of patient-reported outcomes during treatment with deferasirox or deferoxamine for iron overload in patients with β-thalassemia. Clin Ther. 2007;29(5):909-917. (Pubitemid 47241173)
32. Taher A, Al Jefri A, Elalfy MS, et al. Improved treatment satisfaction and convenience with deferasirox in iron-overloaded patients with β-thalassemia: Results from the ESCALATOR Trial. Acta Haematol. 2010;123(4):220-225.
33. Cappellini MD, Porter J, El-Beshlawy A, et al. Tailoring iron chelation by iron intake and serum ferritin: the prospective EPIC study of deferasirox in 1744 patients with transfusion-dependent anemias. Haematologica. 2010;95(4):557-566.
34. Pennell DJ, Porter JB, Cappellini MD, et al. Efficacy of deferasirox in reducing and preventing cardiac iron overload in β-thalassemia. Blood. 2010;115(12):2364-2371.
35. * over two years of deferasirox therapy in β-thalassemia major patients with cardiac iron overload. Haematologica. 2011;96(1):48-54.
36. * in patients with β-thalassemia major treated with deferasirox (Exjade®) for up to 3 years (Abstract 4276). Blood. 2010;116(21):4276.
37. Wood JC, Kang BP, Thompson A, et al. The effect of deferasirox on cardiac iron in thalassemia major: impact of total body iron stores. Blood. 2010;116(4):537-543.
38. Pepe A, Meloni A, Capra M, et al. Deferasirox, deferiprone and desferrioxamine treatment in thalassemia major patients: cardiac iron and function comparison determined by quantitative magnetic resonance imaging. Haematologica. 2011;96(1):41-47.
39. Musallam KM, Taher AT. Deferiprone or deferasirox for cardiac siderosis in β-thalassemia major. Haematologica. 2011;96(2):e5-e6; author reply: e7-e8.
40. Ponticelli C, Musallam KM, Cianciulli P, Cappellini MD. Renal complications in transfusiondependent β thalassaemia. Blood Rev. 2010;24(6):239-244.
41. Rienhoff HY Jr, Viprakasit V, Tay L, et al. A phase 1 dose-escalation study: safety, tolerability, and pharmacokinetics of FBS0701, a novel oral iron chelator for the treatment of transfusional iron overload. Haematologica. 2011;96(4):521-525.